Wu ZW, Sha Y, Chen Q, Hou J, Sun Y, Lu WK, Chen J, Yu LJ. Novel intergenic KIF5B-MET fusion variant in a patient with gastric cancer: A case report. World J Clin Cases 2021; 9(14): 3350-3355 [PMID: 34002144 DOI: 10.12998/wjcc.v9.i14.3350]
Corresponding Author of This Article
Li-Jiang Yu, BMed, Chief Physician, Department of Oncology, The Seventh Affiliated Hospital of Yangzhou University, Jingjiang People's Hospital, No. 28 Zhongzhou Road, Jingjiang 214500, Jiangsu Province, China. yulijiang830@163.com
Research Domain of This Article
Pathology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. May 16, 2021; 9(14): 3350-3355 Published online May 16, 2021. doi: 10.12998/wjcc.v9.i14.3350
Novel intergenic KIF5B-MET fusion variant in a patient with gastric cancer: A case report
Zhi-Wei Wu, Yu Sha, Qing Chen, Juan Hou, Yan Sun, Wang-Kun Lu, Jing Chen, Li-Jiang Yu
Zhi-Wei Wu, Qing Chen, Juan Hou, Yan Sun, Wang-Kun Lu, Li-Jiang Yu, Department of Oncology, The Seventh Affiliated Hospital of Yangzhou University, Jingjiang People's Hospital, Jingjiang 214500, Jiangsu Province, China
Yu Sha, Jing Chen, Department of Pathology, The Seventh Affiliated Hospital of Yangzhou University, Jingjiang People's Hospital, Jingjiang 214500, Jiangsu Province, China
Author contributions: Yu LJ and Wu ZW designed the study; Wu ZW, Chen Q, and Hou J drafted the manuscript; Sha Y and Chen J conducted the histological and immunohistochemical evaluations; Sha Y and Lu WK performed the NGS analysis; all authors read and approved the final manuscript.
Informed consent statement: Written informed consent was obtained from the patient for publication of his clinical details and clinical images in this case report.
Conflict-of-interest statement: The authors declare no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Jiang Yu, BMed, Chief Physician, Department of Oncology, The Seventh Affiliated Hospital of Yangzhou University, Jingjiang People's Hospital, No. 28 Zhongzhou Road, Jingjiang 214500, Jiangsu Province, China. yulijiang830@163.com
Received: November 25, 2020 Peer-review started: November 25, 2020 First decision: January 7, 2021 Revised: January 20, 2021 Accepted: March 3, 2021 Article in press: March 3, 2021 Published online: May 16, 2021 Processing time: 154 Days and 21 Hours
Abstract
BACKGROUND
MET fusion is a key driver mutation, but it is rare in gastric cancer (GC). Several MET (hepatocyte growth factor receptor) inhibitors have been approved for the treatment of MET-positive patients, but the tumor response is heterogeneous. With the development of next-generation sequencing, diverse MET fusion partner genes have been identified. We herein report a fusion variant involving KIF5B-MET in GC.
CASE SUMMARY
After thoracoscopic inferior lobectomy plus lymph node dissection under general anesthesia, a “tumor within a tumor” was found in the lung tumor tissue of a 64-year-old non-smoking male patient. Combining the medical history and the results of enzyme labeling, the focal area was considered to be GC. To seek potential therapeutic regimens, an intergenic region between KIF5B and MET fusion was identified. This fusion contains a MET kinase domain and coil-coiled domains encoded by KIF5B exons 1-25, which might drive the oncogenesis.
CONCLUSION
Our finding could extend the spectrum and genomic landscape of MET fusions in GC and favor the development of personalized therapy.
Core Tip: In this case report, we report the discovery of a "tumor within a tumor " in the lung tumor tissue of a 64-year-old non-smoking male patient. Combined with the medical history and the results of enzyme labeling, the focal area of the postoperative pathology was considered to be gastric cancer. To seek potential therapeutic regimens, an intergenic region between KIF5B and MET fusion was identified, which contains a MET kinase domain and a coil curl domain encoded by KIF5B exons 1-25, which may drive the tumorigenesis.
